By Madhu Raghunathan, Product Strategy Leader at GE Healthcare Life Sciences
In today’s bioprocessing industry, there is an increasing demand to cut costs while ensuring that product quality is not compromised whatsoever.
Specifically, improvements in productivity and efficiency are ranked as the single most important area on which the biomanufacturing industry should focus its efforts (12th Annual BioPlan report 2015).
These improvements are relevant for both existing and new facilities, and agility and flexibility in production are key elements. Novel technologies and innovative process strategies, such as intensified processing, enable more efficient biomanufacturing operations, even for existing facilities.
Better expression systems, media & process control strategies, and improvements in bioprocessing equipment have led to improved Upstream efficiencies and increased titers. With these improvements, new, and previously unexplored, challenges arise. Downstream processes need to handle higher amounts of both target protein and impurities. So, to make full use of the upstream advances, downstream processes must be intensified.
Process intensification can be thought of as a toolbox comprising of a set of tools that include technologies and solutions such as – single use technology, automated column packing, continuous processing, inline buffer conditioning, etc. – that when applied independently, or in conjunction with each other, can significantly improve the overall efficiency and process economics of existing or stickbuilt facilities.
Madhu Raghunathan is speaking on the various methods for improving downstream operations, including details of the techniques, process economics and case studies on Day 2 the BioProcess International European Summit in Vienna (Unlocking the Potential for Efficiency in Downstream Bioprocesses). See the full agenda from 11th-14th April and register for tickets here.